Showing 5461-5470 of 8840 results for "".
- Study Seeks to Evaluate V. Dox Technology's Ability to Improve Healing Following HS Surgical Procedurehttps://practicaldermatology.com/news/study-seeks-to-evaluate-v-dox-technologys-ability-to-improve-healing-following-hs-surgical-procedure/2460958/The first patient has been enrolled in a new study using Vomaris Innovations, Inc.’s s bioelectric antimicrobial wound care technology following surgical treatment for Hidradenitis Suppurativa (HS). When tunnels develop under the skin in HS, a surgical procedure called deroofing i
- Safety Concerns Fuel Vaccine Hesitancy in PsO Patients on Biologics, But Data Fail to Show Increased Riskhttps://practicaldermatology.com/news/safety-concerns-fuel-vaccine-hesitancy-in-pso-patients-on-biologics-but-data-fail-to-show-increased-risk/2460947/Safety concerns and concerns about aggravation of their underlying condition are common drivers of COVID-19 vaccine hesitancy among patients with psoriatic disease, results of a new study show. Data come from an analysis of social media posts from patients in the US, UK, France, Germany, and
- Experts Highlight Need to Focus on Psoriasis Patients’ Wellbeing in Practicehttps://practicaldermatology.com/news/experts-highlight-need-to-focus-on-psoriasis-patients-wellbeing-in-practice/2460945/In addition to managing the clinical manifestations of psoriasis, clinical practices should implement an overall and holistic assessment of the wellbeing of each patient, says a panel of scientists speaking at a symposium during the European Association of Dermatology and Venereology (EADV) 30th&
- Long-term Extension Study Confirms Benefits of Topical Tapinarof in Psoriasishttps://practicaldermatology.com/news/long-term-extension-study-confirms-benefits-of-topical-tapinarof-in-ad/2460936/Final results from the Phase 3 PSOARING 3 long-term extension study show that Dermavant’s investigational tapinarof 1%, once daily, non-steroidal topical cream for the treatment of plaque psoriasis in adults was well tolerated long term, with a safety
- Bimekizumab Performs Well in Psoriasis with Results Lasting through Two Yearshttps://practicaldermatology.com/news/bimekizumab-performs-well-in-psoriasis-with-results-lasting-through-two-years/2460929/Interim results from the BE BRIGHT open-label extension (OLE) study showed clinical responses observed in bimekizumab-treated psoriasis patients during the first 16 weeks of BE SURE were sustained through to two years of treatment with continuous maintenance dosing, UCB reports. T
- Nutrafol May Promote Hair Growth in Menopausal Womenhttps://practicaldermatology.com/news/nutrafol-may-promote-hair-growth-in-menopausal-women/2460923/Nutrafol may improve hair growth and quality for perimenopausal, menopausal, and postmenopausal women, according to research presented during The North American Menopause Society (NAMS) Annual Meeting in Washington, DC. Researchers compared results at 6 mont
- Dermala Scores New Patent Covering the Use of Human Microbiome to Prevent, Slow, and Reverse Skin Aginghttps://practicaldermatology.com/news/dermala-scores-new-patent-covering-the-use-of-human-microbiome-to-prevent-slow-and-reverse-skin-aging/2460910/Dermala has received issuance of a U.S. Patent to use the human microbiome to slow down the skin aging process. The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adult
- Registration Open for ISHRS Hybrid World Congresshttps://practicaldermatology.com/news/registration-open-for-ishrs-hybrid-world-congress/2460902/The 29th Meeting of the International Society of Hair Restoration Surgery (ISHRS) is coming October 21-23. Registration is now open for the Hybrid World Congress 2021, with the i
- Landmarks and Bridges Go Blue for Alopecia Areata Awareness Monthhttps://practicaldermatology.com/news/landmarks-and-bridges-go-blue-for-alopecia-areata-awareness-month/2460900/Bridges, buildings and other landmarks across the United States will be illuminated blue in recognition of Alopecia Areata Awareness Month this September, The current illumination schedule follows below. Any updates or additions to the schedule will be posted
- Open-label Extension Study Shows Long-term Safety, Efficacy for UCB's Bimekizumab in PsOhttps://practicaldermatology.com/news/open-label-extension-study-shows-long-term-safety-efficacy-for-ucbs-bimekizumab-in-pso/2460883/New interim data from an open-label extension trial to assess the long-term safety, tolerability, and efficacy of bimekizumab show that the majority of patients who achieved complete or near complete skin clearance after 16 weeks of bimekizumab treatment maintained these responses through to